Sight Sciences (SGHT) Set to Post Earnings on Wednesday

Sight Sciences (NASDAQ:SGHT) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $23.55 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.10. Sight Sciences had a negative net margin of 35.69% and a negative return on equity of 43.39%. The firm had revenue of $23.39 million for the quarter, compared to analyst estimates of $21.72 million. On average, analysts expect Sight Sciences to post ($0.48) EPS for the current fiscal year and ($0.37) EPS for the next fiscal year.

Sight Sciences Trading Down 1.8%

Shares of SGHT stock opened at $9.15 on Tuesday. The firm has a fifty day moving average of $8.61 and a 200-day moving average of $6.02. The stock has a market cap of $504.06 million, a price-to-earnings ratio of -16.34 and a beta of 2.45. Sight Sciences has a 52-week low of $3.38 and a 52-week high of $9.71. The company has a debt-to-equity ratio of 0.58, a quick ratio of 4.67 and a current ratio of 4.95.

Analyst Upgrades and Downgrades

SGHT has been the topic of several recent research reports. HC Wainwright started coverage on shares of Sight Sciences in a research report on Thursday, October 15th. They set a “buy” rating and a $14.00 target price on the stock. Citigroup increased their price target on shares of Sight Sciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a research report on Monday, October 5th. Wall Street Zen upgraded shares of Sight Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. UBS Group lifted their price objective on Sight Sciences from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a research note on Friday, August 7th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Sight Sciences has a consensus rating of “Moderate Buy” and an average price target of $9.25.

Insider Activity

In related news, CEO Paul Badawi sold 29,653 shares of Sight Sciences stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.05, for a total transaction of $268,359.65. Following the completion of the transaction, the chief executive officer directly owned 6,092,819 shares of the company’s stock, valued at $55,140,011.95. This trade represents a 0.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO James Rodberg sold 7,208 shares of the business’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $8.85, for a total transaction of $63,790.80. Following the completion of the transaction, the chief financial officer owned 216,829 shares in the company, valued at approximately $1,918,936.65. This trade represents a 3.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 47,646 shares of company stock valued at $429,157. Company insiders own 30.40% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.